VICPLAS INTERNATIONAL LTD
(COMPANY REGISTRATION NO. 199805362R)
FULL-YEAR FINANCIAL STATEMENT FOR THE YEAR ENDED 31 JULY 2018

1(a) An income statement for the Group together with a comparative statement for the corresponding period of the immediately preceding financial year.

	Group		
	S$'000		%
	31 Jul 2018	31 Jul 2017	Increase/(Decrease)
Revenue	**68,673**	**63,710**	**7.8**
Other income	2,682	4,074	(34.2)
Changes in inventories of finished goods and work-in progress	1,142	(392)	nm
Raw materials and consumables used	(29,095)	(25,724)	13.1
Purchase of finished goods for resale	(2,476)	(2,115)	17.1
Employee benefits expense	(21,273)	(18,971)	12.1
Depreciation and amortisation expenses	(3,572)	(3,404)	4.9
Changes in fair value of investment property	482	-	nm
Other operating expenses	(14,836)	(13,289)	11.6
Finance costs	(147)	(132)	11.4
Profit before tax	**1,580**	**3,757**	**(57.9)**
Income tax	1,348	(591)	nm
Profit after tax	**2,928**	**3,166**	**(7.5)**
Other comprehensive income (loss), net of tax:			
Items that may be reclassified subsequently to profit or loss:			
Exchange differences on translation of foreign operations	63	(195)	nm
Other comprehensive income (loss), net of tax	63	(195)	nm
Total comprehensive income	**2,991**	**2,971**	**0.7**
Profit attributable to:			
Owners of the Company	2,950	3,206	(8.0)
Non-controlling interests	(22)	(40)	(45.0)
	2,928	3,166	(7.5)
Total comprehensive income attributable to:			
Owners of the Company	3,013	3,011	0.1
Non-controlling interests	(22)	(40)	(45.0)
	2,991	2,971	0.7

1(b)(i) A statement of financial position for the issuer and Group together with a comparative statement as at the end of the immediately preceding financial year.

	Group		Company	
	31 Jul 2018 S$'000	31 Jul 2017 S$'000	31 Jul 2018 S$'000	31 Jul 2017 S$'000
ASSETS				
Current assets:				
Cash and cash equivalents	7,892	16,313	235	2,035
Trade receivables	19,376	19,038	-	-
Other receivables	2,116	2,567	38,148	37,047
Inventories	11,992	5,928	-	-
Total current assets	41,376	43,846	38,383	39,082
Non-current assets:				
Property, plant and equipment	20,166	17,488	-	-
Investment property	6,502	6,020	-	-
Joint venture	1,168	-	-	-
Intangible assets	1,201	1,181	-	-
Deferred tax assets	2,500	1,500	-	-
Subsidiaries	-	-	40,469	40,222
Total non-current assets	31,537	26,189	40,469	40,222
Total assets	**72,913**	**70,035**	**78,852**	**79,304**
LIABILITIES AND EQUITY				
Current liabilities:				
Bank borrowings	2,810	1,331	-	-
Trade payables	4,490	2,795	-	-
Other payables	5,979	5,202	1,547	1,294
Current portion of finance leases	172	254	-	-
Income tax payable	15	576	-	41
Total current liabilities	13,466	10,158	1,547	1,335
Non-current liabilities:				
Finance leases	142	314	-	-
Bank borrowings	-	15	-	-
Deferred tax liabilities	1,522	1,534	-	-
Total non-current liabilities	1,664	1,863	-	-
Capital and reserves:				
Share capital	50,407	50,053	50,407	50,053
Treasury shares	(37)	(37)	(37)	(37)
Share option reserve	1,372	1,169	1,372	1,169
Currency translation reserve	(950)	(1,013)	-	-
Revaluation reserve	2,965	2,965	-	-
Retained earnings	4,071	4,900	25,563	26,784
Equity attributable to owners of the Company	57,828	58,037	77,305	77,969
Non-controlling interests	(45)	(23)	-	-
Total equity	57,783	58,014	77,305	77,969
Total liabilities and equity	**72,913**	**70,035**	**78,852**	**79,304**

Notes : -

1 Revenue comprises:

	31 Jul 2018 S$'000	31 Jul 2017 S$'000
Medical devices	30,364	24,930
Pipes and pipe fittings	38,309	38,780
Total	68,673	63,710

2 Other income comprises:

	31 Jul 2018 S$'000	31 Jul 2017 S$'000
Gain on disposal of property, plant and equipment	-	36
Interest income from outside parties	7	35
Reversal of allowance for doubtful trade receivables	-	91
Income from tooling, mould and maintenance services	1,695	3,078
Miscellaneous income, net:		
-Ultimate holding company	-	23
-Outside parties	827	622
Foreign exchange gain, net	-	25
Rental income:		
-Subsidiaries of the ultimate holding company	72	72
-Outside parties	12	29
Government grant	69	63
Total	2,682	4,074

3 Other operating expenses comprises:

	31 Jul 2018 S$'000	31 Jul 2017 S$'000
Advertisement and marketing expenses	(1,019)	(997)
Allowance for doubtful trade receivables	(105)	-
Allowance for inventory obsolescence	(6)	(67)
Audit fees	(233)	(212)
Computer expenses	(97)	(95)
Factory consumables	(461)	(343)
Foreign exchange loss, net	(424)	-
Insurance	(467)	(530)
Inventories written down to net realisable value	(62)	(31)
Laboratory and testing	(162)	(118)
Loss on disposal of property, plant and equipment	(9)	-
Professional fees	(816)	(604)
Packaging materials	(450)	(390)
Property tax	(155)	(158)
Rental of premises and equipment	(1,327)	(1,366)
Repair and maintenance	(902)	(581)
Sterilisation and decontamination	(100)	(177)
Tooling expenses	(585)	(1,194)
Transportation and freight	(1,359)	(1,075)
Travelling and entertainment	(662)	(645)
Upkeep of factory premises	(515)	(446)
Upkeep of vehicles	(359)	(290)
Water and electricity	(2,201)	(2,056)
Others	(2,360)	(1,914)
Total	(14,836)	(13,289)

4 Income tax expenses comprises:

	31 Jul 2018 S$'000	31 Jul 2017 S$'000
Current tax	(94)	(423)
Adjustment in respect of over (under) provision of current tax in prior year	474	(84)
Deferred tax	1,012	(26)
Withholding tax	(44)	(58)
Income tax expense for the year	1,348	(591)

Withholding tax arises from interests and rental charges to subsidiaries.

5 nm – not meaningful

1(b)(ii) Aggregate amount of Group's borrowings and debt securities.

Amount repayable in one year or less, or on demand

As at 31 Jul 2018		As at 31 Jul 2017	
Secured S$'000	Unsecured S$'000	Secured S$'000	Unsecured S$'000
2,982	-	1,585	-

Amount repayable after one year

As at 31 Jul 2018		As at 31 Jul 2017	
Secured S$'000	Unsecured S$'000	Secured S$'000	Unsecured S$'000
142	-	329	-

Details of any collateral

The Group's bank borrowings are secured by way of legal mortgages over its leasehold land property of carrying value of approximately $4,856,000 (31 July 2017: $5,126,000) and investment property $6,502,000 (31 July 2017: $6,020,000) and a corporate guarantee by the Company of $15,985,000 (31 July 2017: $15,985,000). The Group's obligations under finance leases are secured by the lessors' title to the leased assets with carrying value of approximately $463,000 (31 July 2017: $566,000).

1(c) A statement of cash flows for the Group together with a comparative statement for the corresponding period of the immediately preceding financial year.

	1 Aug 2017 to 31 Jul 2018 S$'000	1 Aug 2016 to 31 Jul 2017 S$'000
Operating activities:		
Profit before income tax	1,580	3,757
Adjustments for:		
Allowance (Reversal of allowance) for doubtful trade receivables	105	(91)
Allowance for inventory obsolescence	6	67
Inventories written down to net realisable value	62	31
Amortisation of intangible assets	33	33
Depreciation of property, plant and equipment	3,539	3,371
Loss (Gain) on disposal of property, plant and equipment	9	(36)
Change in fair value of investment property	(482)	-
Interest income	(7)	(35)
Interest expense	147	132
Share-based payment expenses	203	130
Operating cash flows before movements in working capital	5,195	7,359
Trade receivables	(385)	(2,359)
Other receivables	617	565
Inventories	(6,274)	1,125
Trade payables	1,704	(113)
Other payables	766	429
Cash generated from operations	1,623	7,006
Interest paid	(147)	(132)
Interest received	7	35
Income taxes paid	(225)	(1,608)
Net cash from operating activities	1,258	5,301
Investing activities:		
Purchase of property, plant and equipment (see (a))	(6,417)	(2,932)
Deposit placed for purchase of property, plant and equipment	(160)	-
Proceeds on disposal of property, plant and equipment	175	41
Addition to intangible asset	(53)	-
Investment in a joint venture	(1,168)	-
Payment for second tranche purchase consideration of a subsidiary	-	(500)
Net cash used in investing activities	(7,623)	(3,391)
Financing activities:		
Proceeds from (Repayment of) bank borrowings (net)	1,463	(198)
Repayments of obligations under finance leases	(254)	(330)
Proceeds from exercise of share options	354	246
Dividend paid	(3,779)	(3,751)
Net cash used in financing activities	(2,216)	(4,033)
Net decrease in cash and cash equivalents	(8,581)	(2,123)
Cash and cash equivalents at beginning of year	16,313	18,486
Effect of foreign exchange rate changes	160	(50)
Cash and cash equivalents at end of year	7,892	16,313
Analysis of the balances of cash and cash equivalents:		
Cash and bank balances	7,892	16,313

Note (a):
During the year, the Group acquired property, plant and equipment with an aggregate cost of $6,426,000 (31 July 2017: $2,618,000) of which $117,000 (31 July 2017: $108,000) remain unpaid at year end. Cash payments of $6,417,000 (31 July 2017: S$2,932,000) were made to purchase property, plant and equipment of which $108,000 (31 July 2017: $422,000) pertains to payment of prior year outstanding balance.

1(d)(i) A statement for the issuer and Group showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders together with a comparative statement for the corresponding period of the immediately preceding financial year.

	Share capital	Treasury shares	Share option reserve	Currency translation reserve	Revaluation reserve	Retained earnings	Total	Non-controlling interest	Total equity
	S$'000	S$'000	S$'000	S$'000	S$'000	S$'000	S$'000	S$'000	S$'000
FY 2018									
Group									
Balance at 31 Jul 2017	50,053	(37)	1,169	(1,013)	2,965	4,900	58,037	(23)	58,014
Total comprehensive income for the year:									
Profit for the year	-	-	-	-	-	2,950	2,950	(22)	2,928
Other comprehensive income for the year	-	-	-	63	-	-	63	-	63
Total	-	-	-	63	-	2,950	3,013	(22)	2,991
Transactions with owners, recognised directly in equity:									
Exercise of share options	354	-	-	-	-	-	354	-	354
Dividends	-	-	-	-	-	(3,779)	(3,779)	-	(3,779)
Recognition of share-based payment	-	-	203	-	-	-	203	-	203
Total	354	-	203	-	-	(3,779)	(3,222)	-	(3,222)
Balance at 31 Jul 2018	50,407	(37)	1,372	(950)	2,965	4,071	57,828	(45)	57,783
Company									
Balance at 31 Jul 2017	50,053	(37)	1,169	-	-	26,784	77,969		
Total comprehensive income for the year:									
Profit for the year	-	-	-	-	-	2,558	2,558		
Transactions with owners, recognised directly in equity:									
Exercise of share options	354	-	-	-	-	-	354		
Dividends	-	-	-	-	-	(3,779)	(3,779)		
Recognition of share-based payment	-	-	203	-	-	-	203		
Total	354	-	203	-	-	(3,779)	(3,222)		
Balance at 31 Jul 2018	50,407	(37)	1,372	-	-	25,563	77,305		
FY 2017									
Group									
Balance at 31 Jul 2016	49,807	(37)	1,039	(818)	2,965	5,445	58,401	17	58,418
Total comprehensive income for the year:									
Profit for the year	-	-	-	-	-	3,206	3,206	(40)	3,166
Other comprehensive loss for the year	-	-	-	(195)	-	-	(195)	-	(195)
Total	-	-	-	(195)	-	3,206	3,011	(40)	2,971
Transactions with owners, recognised directly in equity:									
Exercise of share options	246	-	-	-	-	-	246	-	246
Dividends	-	-	-	-	-	(3,751)	(3,751)	-	(3,751)
Recognition of share-based payment	-	-	130	-	-	-	130	-	130
Total	246	-	130	-	-	(3,751)	(3,375)	-	(3,375)
Balance at 31 Jul 2017	50,053	(37)	1,169	(1,013)	2,965	4,900	58,037	(23)	58,014
Company									
Balance at 31 Jul 2016	49,807	(37)	1,039	-	-	28,004	78,813		
Total comprehensive income for the year:									
Profit for the year	-	-	-	-	-	2,531	2,531		
Transactions with owners, recognised directly in equity:									
Exercise of share options	246	-	-	-	-	-	246		
Dividends	-	-	-	-	-	(3,751)	(3,751)		
Recognition of share-based payment	-	-	130	-	-	-	130		
Total	246	-	130	-	-	(3,751)	(3,375)		
Balance at 31 Jul 2017	50,053	(37)	1,169	-	-	26,784	77,969		

1(d)(ii) Details of any changes in the company's share capital arising from rights issue, bonus issue, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or any other purpose since the end of the previous period reported on. State also the number of shares that may be issued on conversion of all the outstanding convertibles as well as the number of shares of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.

Changes in share capital

	Number of shares			
	As at 31 Jul 2018		As at 31 Jul 2017	
	Number of shares	$'000	Number of shares	$'000
Balance at the beginning of the financial period	501,427,699	50,053	498,727,699	49,807
Issue of shares pursuant to the exercise of share options	4,250,000	354	2,700,000	246
Balance at the end of the financial period	505,677,699	50,407	501,427,699	50,053

Outstanding share options

Grant date	Exercise price per share	Number of share options					Exercise period
		As at 31 Jul 2017	Issued	Forfeited	Exercised	As at 31 Jul 2018	
	$						
1 April 2011	0.075	500,000	-	(500,000)	-	-	2 April 2012 to 1 April 2021
27 March 2014	0.067	1,500,000	-	-	(1,500,000)	-	28 March 2015 to 27 March 2019
19 November 2014	0.073	2,250,000	-	-	(1,500,000)	750,000	20 November 2015 to 19 November 2019
18 January 2016	0.115	3,750,000	-	-	(1,250,000)	2,500,000	19 January 2017 to 18 January 2021
18 January 2016	0.115	10,000,000	-	-	-	10,000,000	19 January 2017 to 18 January 2026
23 January 2017	0.108	13,000,000	-	-	-	13,000,000	24 January 2018 to 23 January 2022
		31,000,000	-	(500,000)	(4,250,000)	26,250,000	

1(d)(iii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year.

The total number of issued shares excluding treasury shares:

	As at 31 Jul 2018	As at 31 Jul 2017
Number of issued shares	505,677,699	501,427,699
Treasury shares	461,000	461,000
Number of issued shares excluding treasury shares	505,216,699	500,966,699

1(d)(iv) A statement showing all sales, transfers, disposal, cancellation and/or use of treasury shares as at the end of the current financial period reported on.

	As at 31 Jul 2018		As at 31 Jul 2017	
	Number of shares	S$'000	Number of shares	S$'000
Balance at the beginning of the financial period	461,000	37	461,000	37
Balance at the end of the financial period	461,000	37	461,000	37

There were no sales, transfers, disposal, cancellation and/or use of treasury shares as at the end of the current financial period reported on.

2 Whether the figures have been audited or reviewed and in accordance with which auditing standard or practice.

The figures have not been audited or reviewed by our auditors.

3 Where the figures have been audited or reviewed, the auditors' report (including any qualifications or emphasis of a matter).

Not applicable.

4 Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied.

The Group has applied the same accounting policies and methods of computations in the financial statement consistent with those of the most recent audited financial statement as at 31 July 2017.

The adoption of these new/revised accounting standards (including its consequential amendments) and interpretations does not result in changes to the Group's and Company's accounting policies and has no material effect on the full year announcement.

5 If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change.

Not applicable.

6 Earnings per ordinary share of the group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends.

	31 Jul 2018 (in cents)	31 Jul 2017 (in cents)
Earnings per ordinary share for the period based on the profit after tax attributable to shareholders		
(a) Based on weighted average number of ordinary shares in issue	0.59	0.64
- Weighted average number of shares	503,261,904	499,913,822
(b) On a fully diluted basis	0.59	0.64
- Adjusted weighted average number of shares	503,897,034	503,169,627

7 Net asset value for the issuer and group per ordinary share based on the total number of issued shares excluding treasury shares of the issuer at the end of the current financial period reported on and the immediately preceding financial year.

Group

	31 Jul 2018 (in cents)	31 Jul 2017 (in cents)
Net asset value per ordinary share	11.44	11.58

Company

	31 Jul 2018 (in cents)	31 Jul 2017 (in cents)
Net asset value per ordinary share	15.30	15.56

The calculation of net asset value per ordinary share is based on 505,216,699 ordinary shares in issue excluding treasury shares as at 31 July 2018 (31 July 2017: 500,966,699 ordinary shares).

8 A review of the performance of the group to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following: -

(a) Any significant factors that affected the turnover, costs and earnings of the group for the current period reported on, including (where applicable) seasonal or cyclical factors; and
(b) Any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current period reported on.

Income statement

Revenue for the Company and its subsidiaries (the "Group") increased to $68.7 million for the year ended 31 July 2018 ("FY2018") as compared to $63.7 million for the year ended 31 July 2017 ("FY2017") driven by higher revenue from medical devices segment. The revenue for the medical devices segment was $30.4 million in FY2018, an increase of 21.8% from FY2017 due to increased orders from its customers. The pipes and pipe fittings segment recorded revenue of $38.3 million in FY2018, slightly decreased by 1.2% from FY2017.

Other income was lower in FY2018 due to fewer tools built for customers.

Raw material and consumables used increased by 13.1% due to increased revenue in the medical devices segment and a change in product mix in the pipes and pipe fittings segment. With the continued slow down in residential home projects in Singapore, the pipes and pipe fittings segment sold less products used in residential home projects though it sold more products used in civil engineering projects in FY2018 as compared to FY2017.

Purchase of finished goods for resale increased due to higher demand for purchased products by customers for civil engineering projects in FY2018.

Employee benefits expense increased in FY2018 due to additional headcount and overtime in the medical devices segment to meet the increase in customer orders.

The changes in fair value of investment property arose from the recognition of the fair value of the investment property in Singapore.

Other operating expenses increased mainly due to higher foreign exchange loss, professional fees and other variable costs which had increased with higher level of usage or activities, such as repair and maintenance costs, transportation and freight and utilities costs.

Income tax was a credit of $1.3 million in FY2018 due to the recognition of deferred tax assets of $1 million from unutilised tax losses in Forefront Medical Technology (Jiangsu) Co., Ltd. and reversal of overprovision for prior year tax of $0.4 million, partially offset by FY2018 tax expense of approximately $0.1 million.

Notwithstanding the higher revenue for the medical devices segment, the FY2018 result of the medical devices segment was a loss of $1.4 million as compared to a loss of $0.8 million in FY2017 due primarily to costs incurred for new projects as well as lower income from building fewer tools for customers. Whilst the revenue for the pipes and pipe fittings segment decreased slightly, the FY2018 result of the pipes and pipe fittings segment was $6.0 million as compared to $7.5 million in FY2017 due primarily to decreasing margins from higher costs and increasing competition. Overall, after taking into account the above-mentioned recognition of deferred tax assets, the Group recorded a net profit after tax of $2.9 million in FY2018 as compared to $3.2 million in FY2017.

Statement of financial position

Inventories increased from $5.9 million in FY2017 to $12.0 million in FY2018 due to higher inventory level in the medical devices segment to cater for the increase in customer orders.

Property, plant and equipment increased mainly due to additions in the medical devices segment such as cleanroom upgrading and procuring of machines and automation equipment to support new projects.

Joint venture increased due to the partial capital injection made in Cambodia for the new manufacturing facility under the pipes and pipe fittings segment.

Deferred tax assets increased due to the recognition of deferred tax assets from unutilised tax losses in Forefront Medical Technology (Jiangsu) Co., Ltd.

Bank borrowings pertained to trust receipts utilised in the purchase of raw materials for the pipes and pipe fittings segment and a bank loan of $1 million for the medical devices segment to finance its business expansion into new projects.

Trade and other payables increased due primarily to higher level of activities in the medical devices segment.

Cash flow

Net cash from operating activities for FY2018 decreased to $1.3 million from $5.3 million mainly due to lower profits and the increase in working capital requirement (arising from inventories) which was partially offset by higher net payables and lower income tax paid. Income tax paid was higher in FY2017 due to higher taxable profits in the year preceding FY2017.

Net cash used in investing activities increased by $4.2 million in FY2018 mainly due to the $1.2 million investment in a joint venture under the pipes and pipe fittings segment as well as additions mainly in the medical devices segment for plant and equipment.

Net cash used in financing activities decreased in FY2018 mainly due to the net proceeds from bank borrowings.

Overall, the Group had a cash balance of $7.9 million as at 31 July 2018, a decrease of $8.4 million from the prior year.

9 Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.

There was no forecast or prospect statement disclosed to shareholders previously.

10 A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

Medical devices segment

The medical devices segment continued to expand its customer and revenue base in FY2018 together with improvements in product mix and operational efficiency. Notwithstanding the higher revenue, the segment did not improve on its profitability due primarily to costs incurred for new projects as well as lower income from building fewer tools for customers. Whilst the segment is seeing positive signs on its path to regain profitability, it also faces considerable uncertainties in international trading conditions. The segment will continue focusing on broadening and deepening its customer base as well as operational efficiency.

Pipes and pipe fittings segment

The residential homes segment of the construction industry in Singapore is expected to remain challenging. In view of the increased competition and lower demand in the residential homes segment, the pipes and pipe fittings segment will continue to focus on civil engineering projects in Singapore, regional growth and product expansion. The Singapore Government has recently announced a second round of Home Improvement Programme when HDB flats become older. The upgrading of HDB flats over time could be a source of demand for the segment's products. Whilst the land for the manufacturing facility in Cambodia is in the process of being acquired, the segment intends to monitor the emerging market conditions in Cambodia for the time being before proceeding with the next stage of development.

Overall, the Group expects to face challenges amidst uncertainties in the economy and will continue to exercise prudent cost management while developing new business opportunities and strengthening the base for its future growth.

11 Dividend

(a) Current financial period reported on

Any dividend recommend for the current financial period reported on?

Yes.

Name of Dividend	Interim (paid)	Final (proposed)
Dividend Type	Cash	Cash
Dividend Rate	S$0.0025 per ordinary share (one-tier tax exempt)	S$0.005 per ordinary share (one-tier tax exempt)
Tax Rate	N.A	N.A

Directors are pleased to propose a final dividend of S$0.005 per ordinary share (one-tier tax exempt) in respect of the financial year ended 31 July 2018 for approval by shareholders at the next Annual General Meeting. The interim and proposed final dividends amounted to S$0.0075 per ordinary share (one-tier tax exempt).

(b) Corresponding period of the immediately preceding financial year

Any dividend declared for the corresponding period of the immediately preceeding financial year?

Yes.

Name of Dividend	Interim	Final
Dividend Type	Cash	Cash
Dividend Rate	S$0.0025 per ordinary share (one-tier tax exempt)	S$0.005 per ordinary share (one-tier tax exempt)
Tax Rate	N.A	N.A

(c) Date payable

To be announced later.

(d) Books closure date

To be announced later.

12 If no dividend has been declared/recommended, a statement to that effect.

Not applicable.

13 Interested person transactions.

Name of interested person	Aggregate value of all interested person transactions during the financial period under review (excluding transactions less than S$100,000 and transactions under shareholders' mandate pursuant to Rule 920) S$'000	Aggregate value of all interested person transactions conducted under shareholders' mandate pursuant to Rule 920 (excluding transactions less than S$100,000) S$'000
Subsidiaries and associates of Venner Capital S.A.	302	2,092

14 Segmented revenue and results for business or geographical segments of the group in the form presented in the issuer's most recent audited annual financial statements, with comparative information for the immediately preceding year.

	Medical devices		Pipes & pipe fittings		Eliminations		Total	
	31 Jul 2018 S$'000	31 Jul 2017 S$'000	31 Jul 2018 S$'000	31 Jul 2017 S$'000	31 Jul 2018 S$'000	31 Jul 2017 S$'000	31 Jul 2018 S$'000	31 Jul 2017 S$'000
Revenue								
External sales	30,364	24,930	38,309	38,780	-	-	68,673	63,710
Results								
Segment result	(1,377)	(754)	6,015	7,536	(413)	(406)	4,225	6,376
Unallocated expenses							(2,505)	(2,522)
Interest expense	(31)	(59)	(116)	(73)	-	-	(147)	(132)
Interest income	-	-	7	35	-	-	7	35
Profit before income tax							1,580	3,757
Income tax expense					-	-	1,348	(591)
Profit for the year							2,928	3,166
Other information								
Capital expenditure	5,121	1,272	1,305	1,346	-	-	6,426	2,618
Depreciation and amortisation	1,670	1,549	1,902	1,855	-	-	3,572	3,404
Balance Sheet								
Assets								
Segment assets	33,467	28,219	39,191	39,761	-	-	72,658	67,980
Unallocated corporate assets							255	2,055
Consolidated total assets							72,913	70,035
Liabilities								
Segment liabilities	6,989	4,911	6,594	5,775	-	-	13,583	10,686
Unallocated corporate liabilities							1,547	1,335
Consolidated total liabilities							15,130	12,021

Geographical segments	Revenue		Segment assets		Additions to property, plant and equipment	
	31 Jul 2018 S$'000	31 Jul 2017 S$'000	31 Jul 2018 S$'000	31 Jul 2017 S$'000	31 Jul 2018 S$'000	31 Jul 2017 S$'000
Singapore	63,694	59,980	42,480	47,149	1,225	1,313
Malaysia	3,741	3,338	4,364	5,526	161	233
China	1,238	392	26,069	17,360	5,040	1,072
	68,673	63,710	72,913	70,035	6,426	2,618

15 In the review of performance, the factors leading to any material changes in contributions to turnover and earnings by the business or geographical segments.

Please refer to paragraph 8.

16 A breakdown of sales

	Group		
	31 Jul 2018 S$'000	31 Jul 2017 S$'000	Increase/ (Decrease) %
Sales reported for first half	33,960	32,473	4.6
Sales reported for second half	34,713	31,237	11.1
	68,673	63,710	7.8
Profit after tax reported for first half	1,532	1,636	(6.4)
Profit after tax reported for second half	1,396	1,530	(8.8)
	2,928	3,166	(7.5)

17 A breakdown of the total annual dividend (in dollar value) for the issuer's latest full year and its previous full year.

	Latest full year	Previous full year
	S$'000	S$'000
Ordinary shares	3,779	3,751

18 Confirmation of Directors and Executive Officers' undertakings pursuant to Listing Rule 720(1).

The Company has procured undertakings from all of its Directors and relevant Executive Officers in compliance with Listing Rule 720(1).

19 Notification pursuant to Rule 704(13) of the Listing Manual

Report of persons occupying managerial positions in the Company or any of its principal subsidiaries who are relatives of a director or chief executive officer or substantial shareholder of the Company.

Name	Age	Family relationship with any director, chief executive officer and/or substantial shareholder	Current position and duties, and the year the position was first held	Details of changes in duties and position held, if any, during the year
Mr Cheng Hsheng @ Zhong Zixian	41	Son of Mr Cheng Liang (Acting Group Chief Executive Officer)	Group Operations Director with effect from 1 April 2016	Not applicable

BY ORDER OF THE BOARD

Cheng Liang
Acting Group Chief Executive Officer
28 September 2018